Literature DB >> 23183527

Performance of rapid tests for detection of HBsAg and anti-HBsAb in a large cohort, France.

Julie Bottero1, Anders Boyd, Joel Gozlan, Maud Lemoine, Fabrice Carrat, Anne Collignon, Nicolas Boo, Philippe Dhotte, Brigitte Varsat, Gérard Muller, Olivier Cha, Odile Picard, Jean Nau, Pauline Campa, Benjamin Silbermann, Marc Bary, Pierre-Marie Girard, Karine Lacombe.   

Abstract

BACKGROUND & AIMS: The systematic use of rapid tests performed at points-of-care may facilitate hepatitis B virus (HBV) screening and substantially increase HBV infection awareness. The aim of this study was to evaluate the effectiveness of such tests for HBsAg and anti-HBsAb detection among individuals visiting a variety of healthcare centers located in a low HBV-prevalent area.
METHODS: Three rapid tests for hepatitis B surface antigen (HBsAg) detection (VIKIA, Determine and Quick Profile) and one test for anti-hepatitis B surface antibody (anti-HBsAb) detection (Quick Profile) were evaluated in comparison to ELISA serology. Sensitivity (Se), specificity (Sp), positive and negative predictive values (PPV and NPV, respectively) and area under the ROC curve were used to estimate test performance. Non-inferiority criteria of the joint Se, Sp were set at 0.80, 0.95.
RESULTS: Among the 3956 subjects screened, 85 (2.1%) were HBsAg-positive and 2225 (56.5%) had a protective anti-HBsAb titer. Test Se and Sp (lower bound of 97.5% CI) were as follows: 96.5% (89.0%), 99.9% (99.8%) for Vikia; 93.6% (80.7%), 100.0% (99.8%) for Determine; and 90.5% (80.8%), 99.7% (99.5%) for Quick Profile; with all three tests achieving minimal non-inferiority criteria. False negatives were typically observed in inactive HBsAg carriers. The anti-HBsAb Quick Profile test had excellent specificity (97.8%) and PPV (97.8%) albeit low sensitivity (58.3%), thus failing to establish non-inferiority.
CONCLUSIONS: All three HBsAg rapid tests could be considered ideal for HBV screening in low HBV-prevalent countries, given the ease of use, rapidity, and high classification probabilities. The anti-HBsAb Quick Profile could be considered reliable only for positive tests.
Copyright © 2012 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23183527     DOI: 10.1016/j.jhep.2012.11.016

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  21 in total

1.  Comparative Performance of Three Rapid HBsAg Assays for Detection of HBs Diagnostic Escape Mutants in Clinical Samples.

Authors:  Annabelle Servant-Delmas; Thoai Duong Ly; Clémence Hamon; Ali Kassim Houdah; Syria Laperche
Journal:  J Clin Microbiol       Date:  2015-09-16       Impact factor: 5.948

2.  Seroprevalence of chronic hepatitis B virus infection and immunity to measles, rubella, tetanus and diphtheria among schoolchildren aged 6-7 years old in the Solomon Islands, 2016.

Authors:  Lucy Breakwell; Jenniffer Anga; Gretchen Cooley; Laura Ropiti; Sarah Gwyn; Kathleen Wannemuehler; Joseph Woodring; Divinal Ogaoga; Diana Martin; Minal Patel; Rania A Tohme
Journal:  Vaccine       Date:  2020-05-28       Impact factor: 3.641

Review 3.  Accuracy of Rapid Point-of-Care Diagnostic Tests for Hepatitis B Surface Antigen-A Systematic Review and Meta-analysis.

Authors:  Mehnaaz S Khuroo; Naira S Khuroo; Mohammad S Khuroo
Journal:  J Clin Exp Hepatol       Date:  2014-08-28

4.  Field performance of the Determine HBsAg point-of-care test for diagnosis of hepatitis B virus co-infection among HIV patients in Zambia.

Authors:  Caroline C Chisenga; Kalo Musukuma; Roma Chilengi; Samuel Zürcher; Virginia Munamunungu; Alice Siyunda; David Ojok; Sophie Bauer; Gilles Wandeler; Michael Vinikoor
Journal:  J Clin Virol       Date:  2017-11-16       Impact factor: 3.168

Review 5.  Update on hepatitis B and C virus diagnosis.

Authors:  Livia Melo Villar; Helena Medina Cruz; Jakeline Ribeiro Barbosa; Cristianne Sousa Bezerra; Moyra Machado Portilho; Letícia de Paula Scalioni
Journal:  World J Virol       Date:  2015-11-12

6.  Low Level of Hepatitis B Virus Infection in Children 20 Years After Initiation of Infant Vaccination Program in Wallis and Futuna.

Authors:  Lorenzo Pezzoli; Jean Pierre Mathelin; Karen Hennessey; Padmasiri Eswara-Aratchige; Jayaprakash Valiakolleri; Sung Hye Kim
Journal:  Am J Trop Med Hyg       Date:  2017-04-06       Impact factor: 2.345

7.  Validation of rapid point-of-care (POC) tests for detection of hepatitis B surface antigen in field and laboratory settings in the Gambia, Western Africa.

Authors:  Harr Freeya Njai; Yusuke Shimakawa; Bakary Sanneh; Lynne Ferguson; Gibril Ndow; Maimuna Mendy; Amina Sow; Gora Lo; Coumba Toure-Kane; Junko Tanaka; Makie Taal; Umberto D'alessandro; Ramou Njie; Mark Thursz; Maud Lemoine
Journal:  J Clin Microbiol       Date:  2015-01-28       Impact factor: 5.948

8.  Establishment of Magnetic Microparticles-Assisted Time-Resolved Fluoroimmunoassay for Determinating Biomarker Models in Human Serum.

Authors:  Zhi-Qi Ren; Tian-Cai Liu; Si-Hui Zhuang; Guan-Feng Lin; Jing-Yuan Hou; Ying-Song Wu
Journal:  PLoS One       Date:  2015-06-23       Impact factor: 3.240

9.  Current state of and needs for hepatitis B screening: results of a large screening study in a low-prevalent, metropolitan region.

Authors:  Julie Bottero; Anders Boyd; Maud Lemoine; Fabrice Carrat; Joel Gozlan; Anne Collignon; Nicolas Boo; Philippe Dhotte; Brigitte Varsat; Gerard Muller; Olivier Cha; Nadia Valin; Jean Nau; Pauline Campa; Benjamin Silbermann; Marc Bary; Pierre-Marie Girard; Karine Lacombe
Journal:  PLoS One       Date:  2014-03-24       Impact factor: 3.240

10.  High endemicity and low molecular diversity of hepatitis B virus infections in pregnant women in a rural district of North Cameroon.

Authors:  Alexandra Ducancelle; Pierre Abgueguen; Jacques Birguel; Wael Mansour; Adeline Pivert; Hélène Le Guillou-Guillemette; Jean-Jacques Sobnangou; Amélie Rameau; Jean-Marie Huraux; Françoise Lunel-Fabiani
Journal:  PLoS One       Date:  2013-11-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.